Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.9%

9 terminated/withdrawn out of 70 trials

Success Rate

85.5%

-1.0% vs industry average

Late-Stage Pipeline

29%

20 trials in Phase 3/4

Results Transparency

62%

33 of 53 completed trials have results

Key Signals

1 recruiting33 with results7 terminated

Enrollment Performance

Analytics

Phase 2
26(38.2%)
Phase 1
22(32.4%)
Phase 3
18(26.5%)
Phase 4
2(2.9%)
68Total
Phase 2(26)
Phase 1(22)
Phase 3(18)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (70)

Showing 20 of 70 trials
NCT06844487Phase 3Active Not Recruiting

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT02977715Phase 3Completed

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Role: collaborator

NCT07199569Phase 2Active Not Recruiting

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

Role: lead

NCT07003984Phase 3Recruiting

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Role: lead

NCT07467707Phase 3Not Yet Recruiting

An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults

Role: lead

NCT06844500Phase 3Active Not Recruiting

Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT02772562Phase 2Terminated

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

Role: collaborator

NCT06549530Phase 2Active Not Recruiting

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Role: lead

NCT06899802Phase 2Active Not Recruiting

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Role: lead

NCT03547999Phase 2Terminated

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Role: collaborator

NCT06007183Phase 3Active Not Recruiting

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Role: lead

NCT04246671Phase 1Completed

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Role: lead

NCT05329220Phase 3Completed

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Role: lead

NCT03610581Phase 1Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Role: collaborator

NCT05349617Phase 3Completed

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Role: lead

NCT05238025Phase 3Terminated

MVA-BN-RSV Vaccine Trial

Role: lead

NCT03992872Phase 2Completed

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

Role: lead

NCT05077267Phase 2Completed

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

Role: lead

NCT05072080Phase 3Completed

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Role: lead

NCT03376659Phase 1Terminated

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Role: collaborator